Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?
Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett, Laura Labay, James Mullally, Alexander M. Sherwood, Frank Wiegand
Clinical Chemistry March 7, 2023 DOI: 10.1093/clinchem/hvad016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Officer Chapel Vice president Library science Classics Art history Law Management |
Abstract
The clinical evaluation of hallucinogens and other small molecules, conventionally termed psychedelics, has seen a dramatic increase in the past 5 years. Several key clinical trials recently demonstrated the potential efficacy of these compounds in treating a variety of mental health conditions including depression, anxiety, and substance use disorders. Concurrently, the business and patent landscape of hallucinogen derivatives from both conventional drug companies and emerging commercial entities is rapidly expanding.